1. Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults.
- Author
-
Li, APY, Cohen, CA, Leung, NHL, Fang, VJ, Gangappa, S, Sambhara, S, Levine, MZ, Iuliano, AD, Perera, RAPM, Ip, DKM, Peiris, JSM, Thompson, MG, Cowling, BJ, Valkenburg, SA, Li, APY, Cohen, CA, Leung, NHL, Fang, VJ, Gangappa, S, Sambhara, S, Levine, MZ, Iuliano, AD, Perera, RAPM, Ip, DKM, Peiris, JSM, Thompson, MG, Cowling, BJ, and Valkenburg, SA
- Abstract
The vaccine efficacy of standard-dose seasonal inactivated influenza vaccines (S-IIV) can be improved by the use of vaccines with higher antigen content or adjuvants. We conducted a randomized controlled trial in older adults to compare cellular and antibody responses of S-IIV versus enhanced vaccines (eIIV): MF59-adjuvanted (A-eIIV), high-dose (H-eIIV), and recombinant-hemagglutinin (HA) (R-eIIV). All vaccines induced comparable H3-HA-specific IgG and elevated antibody-dependent cellular cytotoxicity (ADCC) activity at day 30 post vaccination. H3-HA-specific ADCC responses were greatest following H-eIIV. Only A-eIIV increased H3-HA-IgG avidity, HA-stalk IgG and ADCC activity. eIIVs also increased polyfunctional CD4+ and CD8+ T cell responses, while cellular immune responses were skewed toward single-cytokine-producing T cells among S-IIV subjects. Our study provides further immunological evidence for the preferential use of eIIVs in older adults as each vaccine platform had an advantage over the standard-dose vaccine in terms of NK cell activation, HA-stalk antibodies, and T cell responses.
- Published
- 2021